5.79
0.17 (3.02%)
| Penutupan Terdahulu | 5.62 |
| Buka | 5.50 |
| Jumlah Dagangan | 1,290,633 |
| Purata Dagangan (3B) | 2,930,014 |
| Modal Pasaran | 746,465,856 |
| Harga / Buku (P/B) | 16.28 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| EPS Cair (TTM) | -1.99 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 16.39% |
| Nisbah Semasa (MRQ) | 10.18 |
| Aliran Tunai Operasi (OCF TTM) | -144.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -96.01 M |
| Pulangan Atas Aset (ROA TTM) | -32.40% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Care Facilities (US) | Menaik | Menaik |
| Medical Care Facilities (Global) | Menaik | Menaik | |
| Stok | COMPASS Pathways Plc - American | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.80 |
|
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360. |
|
| Sektor | Healthcare |
| Industri | Medical Care Facilities |
| % Dimiliki oleh Orang Dalam | 13.64% |
| % Dimiliki oleh Institusi | 55.92% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Gmt Capital Corp | 31 Dec 2025 | 2,844,618 |
| Eagle Health Investments Lp | 31 Dec 2025 | 1,519,388 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 70.00 (HC Wainwright & Co., 1,108.98%) | Beli |
| Median | 21.00 (262.69%) | |
| Rendah | 18.00 (Morgan Stanley, 210.88%) | Beli |
| Purata | 32.50 (461.31%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 8.09 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 02 Mar 2026 | 70.00 (1,108.98%) | Beli | 7.02 |
| Canaccord Genuity | 18 Feb 2026 | 20.00 (245.42%) | Beli | 8.45 |
| Morgan Stanley | 18 Feb 2026 | 18.00 (210.88%) | Beli | 8.45 |
| RBC Capital | 18 Feb 2026 | 22.00 (279.97%) | Beli | 8.45 |
| 23 Jan 2026 | 21.00 (262.69%) | Beli | 7.17 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| LOXAM TERI | 5.64 | - | 75,000 | 423,000 |
| NATH KABIR | 5.64 | - | 175,000 | 987,000 |
| Jumlah Keseluruhan Kuantiti Bersih | 250,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 1,410,000 | |||
| Purata Pembelian Keseluruhan ($) | 5.64 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| LOXAM TERI | Pegawai | 26 Mar 2026 | Diperolehi (+) | 75,000 | 5.64 | 423,000 |
| NATH KABIR | Pegawai | 26 Mar 2026 | Diperolehi (+) | 175,000 | 5.64 | 987,000 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 07 Jan 2026 | Pengumuman | Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |